

**REMARKS**

**Amendments to the Claims**

Upon entry of the amendment, claims 3-11 and 29-31 are pending.

Claims 12-28 have been cancelled and claims 7-11 have been withdrawn, all without prejudice or disclaimer.

Claims 8 and 9 have been amended to recite dependency from "claim 7" in place of "claim 6" to correct an obvious typographical error. This amendment is merely clerical in nature.

Support for new claims 29 and 30 is found throughout the specification and claims as filed, for example, at page 2, lines 8-11; at page 5, lines 5-16; and at pages 9-10, bridging paragraph.

Support for new claim 31 is found throughout the specification and claims as filed, for example, at page 2, lines 12-17; at page 12, line 20 to page 14, line 7, at page 19, lines 14-23, and claim 8 as filed.

Applicants submit that no new matter has been added by way of these amendments. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter or agreement with any objection or rejection of record. Accordingly, entry of the amendment is respectfully requested.

**Information Disclosure Statement**

An Information Disclosure Statement (IDS) is being filed concurrently herewith. Entry of this IDS is respectfully requested.

**Reply to Restriction Requirement**

Responsive to the Restriction Requirement dated June 20, 2008, the claims of Group II (Claims 3-6 and new claims 29-30 now fall within Group II), defined by the Examiner as being drawn to the hybridoma cell line with DSMZ accession number DSM ACC2625 and the anti-idiotypic antibody expression by said hybridoma, are elected for prosecution. Applicant reserves the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicant does not abandon or waive any rights in the non-elected inventions.

**Anticipated Rejoinder of Claims Pursuant to M.P.E.P. § 821.04**


The Examiner has required restriction between product and process claims. Applicants have elected to prosecute the product claims of Group II (Claims 3-6 and new claims 29-30 now fall within the elected group), defined by the Examiner as being drawn to the hybridoma cell line with DSMZ accession number DSM ACC2625 and the anti-idiotypic antibody expression by said hybridoma. If the Examiner withdraws the process claims of Group III (claims 7-11 and new claim 31 now fall within Group III), defined by the Examiner as being drawn to a method of generating an immune response in a mammal against the anti-idiotypic antibody of Group II, Applicants respectfully requests that the Examiner rejoins these claims pursuant to MPEP § 821.04 in the event the independent claims from which they depend are allowed.

**CONCLUSION**

In view of the above remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Date: September 9, 2008  
MEDIMMUNE, INC.  
Customer Number: 36577  
Telephone: (301) 398-4918  
Facsimile: (301) 398-9306

Respectfully submitted,

By:   
\_\_\_\_\_  
Lisa Kreppel  
Agent for Applicants  
Registration No. 56,970